Oculis Holding AG (OCS) Accounts Payables (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Accounts Payables of $5.7 million for Q1 2026, up 18.64% year-over-year from $4.8 million in Q1 2025, and up 154.94% quarter-over-quarter from $2.3 million in Q4 2025.
Oculis Holding AG (OCS) Accounts Payables (2021 - 2026) Analysis & Trends
Oculis Holding AG's Accounts Payables history runs 6 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 18.64% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (up 18.64% YoY), while the FY2025 annual figure was $2.2 million, down 67.47% from the prior year.
- Accounts Payables for Q1 2026 stood at $5.7 million, up from $2.3 million in the prior quarter.
- The five-year high for Accounts Payables was $8.6 million in Q4 2023, with the low at $1.3 million in Q1 2024.
- The 5-year median for Accounts Payables is $4.4 million (2023), against an average of $4.4 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 349.18% in 2022, then sank 72.97% in 2025.
- Oculis Holding AG's Accounts Payables stood at $4.0 million in 2022, then jumped by 113.34% to $8.6 million in 2023, then dropped by 21.74% to $6.7 million in 2024, then tumbled by 66.4% to $2.3 million in 2025, then soared by 154.94% to $5.7 million in 2026.
- Business Quant data shows OCS's Accounts Payables at $5.7 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 3.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.39 Mn |
| Mar 31, 2026 | 5.74 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 4.84 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 3.52 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 8.56 Mn |
| Sep 30, 2023 | 7.60 Mn |
| Jun 30, 2023 | 4.36 Mn |
| Dec 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 893,629.73 |